Phase 3 Pneumococcal disease Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Pneumococcal disease
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.1,920 enrolled1 locationNCT06044077
Recruiting
Phase 3Phase 4
A randomised controlled trial of pneumococcal conjugate vaccines Synflorix and Prevenar13 in sequence or alone in high-risk Indigenous infants (PREV-IX): immunogenicity, carriage and otitis media outcomes
Non-typeable Haemophilus influenzae diseaseOtitis media in Indigenous infantsPneumococcal disease
Menzies School of Health Research425 enrolled1 locationACTRN12610000544077
Active
Phase 3
Preventing Invasive Pneumococcal Disease in Children & Adolescents with Leukaemia
Immunogenicity of pneumococcal vaccination in children and adolescents newly diagnosed with Leukaemia, with the aim to protect them from invasive pneumococcal disease
NHMRC CCRE in Childhood and Adolescent Immunisation100 enrolled1 locationACTRN12609000515291
Completed
Phase 3Phase 4
The immunogenicity of the new pneumococcal conjugate vaccine in the elderly
Pneumococcal disease
Professor C Raina MacIntyre315 enrolled1 locationACTRN12607000387426